Mesothelioma therapeutic agent
AssigneeChugai Seiyaku Kabushiki Kaisha
InventorsNorihiro Nishimoto, Tadamitsu Kishimoto, Yasuo Adachi, Koichi Takayama
Life of this patent
Estimating the term…
Abstract
The present invention provides a mesothelioma therapeutic agent containing an interleukin-6 (IL-6) antagonist such as antibody to IL-6 receptor (IL-6R), and a mesothelioma cell growth inhibitor containing an IL-6 antagonist such as antibody to IL-6R.
Claims27
A method of treating mesothelioma, comprising administering an interleukin-6 (IL-6) antagonist to a patient in need thereof, wherein the IL-6 antagonist is a monoclonal antibody to an IL-6 receptor selected from PM-1 and MR16-1.
A method of inhibiting the growth of a mesothelioma cell, comprising administering an IL-6 antagonist to a patient in need thereof, wherein the antagonist is a monoclonal antibody to an IL-6 receptor selected from PM-1 and MR16-1.
A method of treating mesothelioma, comprising administering a mesothelioma therapeutic agent to a patient in need thereof, wherein the agent comprises an IL-6 antagonist and a pharmaceutically acceptable carrier, and wherein the antagonist is an monoclonal antibody to an IL-6 receptor selected from PM-1 and MR16-1.
Dependencies are inferred from the claim text.